Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 13 - 15 October 2021. These data include 38 abstracts highlighting new longer-term efficacy and safety for both OCREVUS and ENSPRYNG, as well as our ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS. Additional data will show how a deeper scientific understanding of MS and NMOSD in diverse patient populations could ...
Source: Roche Investor Update - October 5, 2021 Category: Pharmaceuticals Source Type: news

Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 13 - 15 October 2021. These data include 38 abstracts highlighting new longer-term efficacy and safety for both OCREVUS and ENSPRYNG, as well as our ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS. Additional data will show how a deeper scientific understanding of MS and NMOSD in diverse patient populations could ...
Source: Roche Media News - October 5, 2021 Category: Pharmaceuticals Source Type: news

MS Treatment Choice May Influence Depression Risk MS Treatment Choice May Influence Depression Risk
Patients with MS who receive rituximab are 28% less likely to develop depression, compared with patients who receive interferons. Depression also may influence adherence to interferons.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 13, 2021 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous trials....
Source: Roche Media News - August 9, 2021 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous trials....
Source: Roche Investor Update - August 9, 2021 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and deb...
Source: Roche Media News - July 21, 2021 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and deb...
Source: Roche Investor Update - July 21, 2021 Category: Pharmaceuticals Source Type: news

Rituximab Seems Safe and Effective for Systemic Sclerosis Rituximab Seems Safe and Effective for Systemic Sclerosis
Rituximab seemed to be a safe and effective treatment for systemic sclerosis in a placebo-controlled validation trial in Japan.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Bayer-submits-regulatory-applications-oncology-treatment-combination-copanlisib-rituximab-US-EU
In the US, Bayer has filed for relapsed indolent B-cell non-Hodgkin’s lymphoma (B-iNHL) / In the EU, Bayer has filed for relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted / Filings based on results from Phase III trial CHRONOS-3 showing a significant improvement in the primary endpoint of progression-free survival for the combination of copanlisib and rituximab in patients with relapsed iNHL (Source: Bayer Company News)
Source: Bayer Company News - June 21, 2021 Category: Pharmaceuticals Source Type: news

Rituximab Superior to Mycophenolate Mofetil in Pemphigus Vulgaris Study Rituximab Superior to Mycophenolate Mofetil in Pemphigus Vulgaris Study
Significantly more patients on rituximab achieved a complete sustained remission in the interim analysis of the trial, which enrolled 135 patients with moderate to severe pemphigus.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 12, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Patients With RA on Rituximab at Risk for Worse COVID Outcomes Patients With RA on Rituximab at Risk for Worse COVID Outcomes
Risk mitigation strategies such as social distancing and wearing masks, especially indoors, remain important for people being treated with rituximab.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - June 8, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news

BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares
Results from a phase 2b trial are"clearly encouraging" and"support the hypothesis that BAFF [B-cell-activating factor] can drive flares after rituximab," said Michael Ehrenstein, MD.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 4, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Lower Steroid Dose Proves Effective for New-Onset ANCA Vasculitis Lower Steroid Dose Proves Effective for New-Onset ANCA Vasculitis
An open-label, randomized trial found that a reduced dose of glucocorticoids added to standard induction therapy with rituximab was safer and no worse than a higher dose at maintaining remission.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 1, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

COVID Vax Response Low in Immune-Mediated Inflammatory Diseases COVID Vax Response Low in Immune-Mediated Inflammatory Diseases
Patients who take methotrexate or rituximab seem to be especially vulnerable.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - May 26, 2021 Category: Infectious Diseases Tags: Rheumatology News Source Type: news